

Prescribing and Medicines Optimisation Guidance

Issue: 19

Date: 14th July 2020

1. NICE: COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders- updated guideline (NG167) ([Link](#))

Recommendation 3.2 in the guideline has been updated to highlight the possible risk of adrenal crisis for patients on long-term corticosteroids.

2. MHRA safety update: Cyproterone acetate: new advice to minimise risk of meningioma ([Link](#))

The risk of meningioma with cyproterone acetate increases with increasing cumulative dose. Use of cyproterone is contraindicated in patients with previous or current meningioma (for all indications) and should only be considered for control of libido in severe hypersexuality or paraphilias in adult men when other interventions are inappropriate. Please see the link above for advice.

3. Evorel Supply Update: July 2020

Following the recent supply problems for the Evorel range of products, Theramex have confirmed the following availability:

Product Name	Dates of Availability
1. Evorel 25	1. Available
2. Evorel 50	2. Intermittent supply first half of July
3. Evorel 75	3. Intermittent supply first half of July
4. Evorel 100	4. Available
5. Evorel Conti	5. Available
6. Evorel Sequi	6. Available

4. NHS England and Improvement extend suspension of eRD consent rules until 30th September 2020. ([Link](#))

Please click on the link to see the full letter which has been released to Primary Care.

5. First Do No Harm – The report of the Independent Medicines and Medical Devices Safety Review. 8 July 2020. ([Link](#))

The report outlines recommendations following the harm caused to patients from the use of:

- Hormone Pregnancy Tests (HPTs)
- **Sodium Valproate**
- Pelvic Mesh Implants

The Review looks at how the healthcare system reacted as a whole, and how this response can be made more robust, speedy and appropriate. There are a number of specific recommendations for each of the interventions, as well as overarching themes. It particularly focuses on the need for the healthcare system to listen to patients, to treat them with respect and to respond to their safety concerns. The report discusses the role played by the MHRA, drug companies as well as clinicians involved.

Please see the link above for the full document.